It’s a bit ironic that when injured people are in pain—and their mobility is reduced—they are often expected to travel to a physical therapy clinic. For millions of people, such trips are a burden. In Australia, however, some patients are “letting movement come to them.” Novel research from The University of Melbourne shows that taking…
Treat-to-target is a widely used approach for rheumatoid arthritis, in which rheumatologists prescribe treatments to reach established benchmarks of disease activity.1 Is it time for a similar approach for fibromyalgia treatment, even though its pathogenesis, disease-activity measures and treatment algorithms are less well understood? Three fibromyalgia researchers present their case in a new paper, “Treat-to-Target…
Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with erosive destruction of diarthrodial joints. Patients who are seropositive are more prone to developing extra-articular manifestations, such as rheumatoid lung, rheumatoid nodules and others. With the development of disease-modifying anti-rheumatic drugs (DMARDs), the incidence and severity of these extra-articular manifestations has declined. Below, we describe…
In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical phenotypes in IIMs. Scientists continue to learn more about how these autoantibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…
Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…
MADRID—Calcification in osteoarthritis (OA) involves a series of pathways and interactions that feed off each other in a process that bears some resemblance to the transformation of cartilage to bone that takes place in the embryonic stage of human development, a researcher said here at the 2017 Annual European Congress on Rheumatology (EULAR). “My hypothesis…
Patients with a diagnosis of rheumatoid arthritis (RA) experience on average double the risk of developing malignant lymphoma when compared with the general population. With the major changes in RA treatment taking place over the past decade, has there been a reduction in the risk of lymphoma in this population? Researchers from the Karolinska Institute…
A two-year study among patients with knee osteoarthritis (OA) showed that steroid injections for knee pain were no more effective than saline injections and actually reduced cartilage volume more than placebo. The study, conducted at Tufts Medical Center in Boston, looked at progression of cartilage loss and change in knee pain after treatment with placebo…
A recent study, conducted by the Vasculitis Clinical Research Consortium and funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), examined whether the addition of abatacept, a drug that affects T cell activation, to standard prednisone treatment could reduce the risk of relapse in patients with giant cell arteritis (GCA).1 Although…
The Rheumatology Informatics System for Effectiveness (RISE) Registry is the ACR’s registry for quality improvement and reporting. Aggregated statistics and trends seen in the RISE Registry will be published monthly in The Rheumatologist. If you have questions about quality reporting, are interested in enrolling in RISE or would like to use data from RISE for…